These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17535081)

  • 1. Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic Drugs.
    Sommerville KW; Dutta S; Biton V; Zhang Y; Cloyd JC; Uthman B
    Clin Drug Investig; 2003; 23(10):661-70. PubMed ID: 17535081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
    Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR
    Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers.
    Dutta S; Zhang Y; Selness DS; Lee LL; Williams LA; Sommerville KW
    Epilepsy Res; 2002 Mar; 49(1):1-10. PubMed ID: 11948003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divalproex to divalproex extended release conversion.
    Dutta S; Reed RC
    Clin Drug Investig; 2004; 24(9):495-508. PubMed ID: 17523712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
    Reed RC; Dutta S; Liu W
    Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation.
    Dutta S; Zhang Y
    Biopharm Drug Dispos; 2004 Nov; 25(8):345-52. PubMed ID: 15378557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.
    Dutta S; Reed RC
    Clin Drug Investig; 2006; 26(12):681-90. PubMed ID: 17274675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
    Reed RC; Dutta S
    Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Is the Best Strategy for Converting from Twice-Daily Divalproex to a Once-Daily Divalproex ER Regimen? : Examinations and Answers via Computer Simulations.
    Reed RC; Dutta S
    Clin Drug Investig; 2004; 24(9):509-21. PubMed ID: 17523713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia.
    Citrome L; Tremeau F; Wynn PS; Roy B; Dinakar H
    J Clin Psychopharmacol; 2004 Jun; 24(3):255-9. PubMed ID: 15118478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex.
    Davis LL; Li X; Bartolucci AA; Williford RB; Lowe JS
    J Clin Psychiatry; 2007 Oct; 68(10):1546-51. PubMed ID: 17960970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration.
    Dutta S; Reed RC; Cavanaugh JH
    Am J Health Syst Pharm; 2004 Nov; 61(21):2280-3. PubMed ID: 15552635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
    Dutta S; Reed RC; Cavanaugh JH
    J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release formulations for the treatment of epilepsy.
    Bialer M
    CNS Drugs; 2007; 21(9):765-74. PubMed ID: 17696575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
    Dutta S; Reed RC
    J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.
    Dutta S; Reed RC
    Epilepsy Res; 2007 Mar; 73(3):275-83. PubMed ID: 17208410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divalproex-ER pharmacokinetics in older children and adolescents.
    Dutta S; Zhang Y; Conway JM; Sallee FR; Biton V; Reed MD; Kearns GL
    Pediatr Neurol; 2004 May; 30(5):330-7. PubMed ID: 15165635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers.
    Dutta S; Zhang Y; Lee LL; O'Dea R
    Biopharm Drug Dispos; 2004 Nov; 25(8):353-7. PubMed ID: 15378556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, Safety, and Retention Rate of Extended-Release Divalproex Versus Conventional Delayed-Release Divalproex: A Meta-Analysis of Controlled Clinical Trials.
    Zhang CQ; Li HY; Wan Y; Bai XY; Gan L; Wang J; Sun HB
    Front Pharmacol; 2022; 13():811017. PubMed ID: 35479307
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects.
    Gordi T; Hou E; Kasichayanula S; Berner B
    Clin Ther; 2008 May; 30(5):909-16. PubMed ID: 18555937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.